Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vapreotide (Debipharm).

P Norman1

  • 1Norman Consulting, Burnham, Bucks, SL1 8JW, UK. Peter.Norman@nationwideisp.net

Idrugs : the Investigational Drugs Journal
|July 28, 2005
PubMed
Summary
This summary is machine-generated.

Vapreotide, a somatostatin analog, is being studied in Phase III trials for prostate cancer and acute esophageal varices bleeding. Further research explores its use in acromegaly, GI disorders, and neuroendocrine tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017
Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016
Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016
Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Oncology
  • Gastroenterology
  • Endocrinology

Background:

  • Vapreotide is a somatostatin analog developed by Debiopharm under license from Tulane University.
  • Somatostatin analogs are crucial in managing various endocrine and gastrointestinal conditions.

Purpose of the Study:

  • To evaluate the efficacy of vapreotide in treating prostate cancer.
  • To assess vapreotide's utility in managing acute bleeding from esophageal varices.
  • To explore potential applications in acromegaly, gastrointestinal fistulae, and neuroendocrine tumors.

Main Methods:

  • Initiation of Phase III clinical trials in France for prostate cancer.
  • Commencement of Phase III trials in France and Asia for acute esophageal varices bleeding.
  • Ongoing investigations into other therapeutic indications.

Related Experiment Videos

Main Results:

  • Phase III trials for prostate cancer and esophageal varices bleeding are currently underway.
  • Preliminary research suggests potential benefits in other related conditions.

Conclusions:

  • Vapreotide shows promise as a therapeutic agent for prostate cancer and gastrointestinal bleeding.
  • Further clinical trials are essential to establish its full therapeutic potential across diverse medical conditions.